Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

1 November 2024

Section 708A Cleansing Statement

This notice is given by Neurizon Therapeutics Limited ACN 094 006 023 (**ASX: NUZ**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

(a) it has today issued a total of 5,071,211 fully paid ordinary shares (**Shares**) as follows:
   (i) 200,000 Shares in relation to the exercise of unlisted options, at an exercise price of $0.10 (10 cents) each;
   (ii) 4,657,895 Shares in relation to the Tranche 2 Placement participation by Related Parties of the Company, including Directors, at an issue price of $0.19 per Share, as approved by shareholders at the Annual General Meeting held on 9 October 2024, pursuant to Resolutions 14, 15, 16, 17 and 18;
   (iii) 54,847 Shares in relation to satisfaction of accrued Director fees to Dr Thomas Duthy (a former Director of the Company) at a deemed issue price of $0.2282 per Share, as approved by shareholders at the Annual General Meeting held on 9 October 2024, pursuant to Resolution 19; and
   (iv) 158,469 Shares in relation to a bonus to an employee of the Company, at a deemed issue price of $0.183 per Share.

(b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

(c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;

(d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:

   (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   (ii) sections 674 and 674A of the Corporations Act; and

(e) as at the date of this notice, there is no "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

The Appendix 2A's relating to the issue of Shares was lodged earlier today.

-Ends-

This announcement is authorised for release by the Board of Directors of Neurizon Therapeutics Limited.

For further information, please contact:

Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Catherine Strong
Sodali & Co
catherine.strong@sodali.com
+61 (0)406 759 268

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

[1] Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951. Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834.

[2] Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015 Jun;262(6):1447-54. doi: 10.1007/s00415-015-7731-6. Epub 2015 Apr 11. PMID: 25860344; PMCID: PMC4469087.